Efficacy and safety of sibeprenlimab in IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials

作者
Zhonghua Tian,Yuxia Li
出处
期刊:BMC Nephrology [BioMed Central]
卷期号:27 (1) 被引量:1
标识
DOI:10.1186/s12882-026-04927-9
摘要

BACKGROUND: IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. A Proliferation-Inducing Ligand (APRIL) plays a critical role in the development and progression of IgAN. This study aimed to evaluate the efficacy and safety of sibeprenlimab, an APRIL receptor antagonist, in IgAN patients. METHODS: A comprehensive literature search was conducted in PubMed, Embase, Web of Science, and Cochrane Library from database inception to November 30, 2025. Randomized controlled trials (RCTs) were identified. Literature quality was assessed using the Cochrane Risk of Bias 2 tool. Data were analyzed using RevMan 5.4. RESULTS: Two high-quality, multi-center, double-blinded RCTs involving 665 primary IgAN patients were included. Compared with the control group, the sibeprenlimab group showed a greater percentage reduction in urine protein-to-creatinine ratio (UPCR) (MD -48.35, 95% CI -62.00 to -34.69, P < 0.00001), a lower proportion of patients experiencing hematuria (OR 0.11, 95% CI 0.06 to 0.20, P < 0.00001), a lower least-squares mean change in estimated glomerular filtration rate (eGFR) (MD 6.11, 95% CI 2.06 to 10.16, P = 0.003), and a marked decrease in circulating galactose-deficient IgA1 (Gd-IgA1) and serum APRIL levels (mean reductions of 66.0% and 95.8%, respectively). Although the overall incidence of adverse events was comparable (OR 0.90, 95% CI 0.39 to 2.09, P = 0.80), the sibeprenlimab group experienced a greater reduction in serum IgG, IgA, and IgM levels than the control group (mean reductions of 35.0%, 66.5%, and 74.8%, respectively). CONCLUSIONS: Current limited but robust evidence suggests that sibeprenlimab is effective in reducing proteinuria and hematuria, lowering circulating Gd-IgA1 and serum APRIL levels, and slowing the decline in eGFR in IgAN patients. Although sibeprenlimab exhibits an overall favorable safety profile, it may be associated with reductions in serum IgG, IgA, and IgM levels. CLINICAL TRIAL NUMBER: Not applicable.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
扶摇完成签到,获得积分10
刚刚
寒冷的穆发布了新的文献求助10
刚刚
可可西里发布了新的文献求助30
刚刚
落卿完成签到 ,获得积分20
刚刚
打打的应助被无情的便当采纳,获得10
1秒前
1秒前
在水一方的应助被槑槑采纳,获得10
1秒前
海边看日落完成签到,获得积分10
2秒前
析木发布了新的文献求助10
2秒前
Jason完成签到 ,获得积分10
2秒前
Zoiiiio发布了新的文献求助10
2秒前
3秒前
3秒前
3秒前
李健的小迷弟的应助被辰伍采纳,获得10
4秒前
FashionBoy的应助被巫凝天采纳,获得10
4秒前
4秒前
黄小皮完成签到,获得积分20
4秒前
纪诗筠完成签到,获得积分20
4秒前
大宝君发布了新的文献求助30
4秒前
4秒前
4秒前
4秒前
5秒前
碎觉觉发布了新的文献求助10
5秒前
5秒前
杨三多发布了新的文献求助10
6秒前
周杨完成签到 ,获得积分10
6秒前
6秒前
6秒前
太阳发布了新的文献求助10
6秒前
7秒前
7秒前
xiamovivi完成签到,获得积分0
7秒前
7秒前
然大宝完成签到,获得积分10
8秒前
阿垚完成签到,获得积分10
9秒前
平常的秋天完成签到,获得积分20
9秒前
lsbbbei发布了新的文献求助10
9秒前
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8162755
求助须知:如何正确求助?哪些是违规求助? 9557016
关于积分的说明 21737907
捐赠科研通 7753093
什么是DOI,文献DOI怎么找? 3427901
关于科研通互助平台的介绍 2552719
邀请新用户注册赠送积分活动 2472528